Active surveillance is a feasible and safe strategy in selected patients with papillary thyroid cancer and suspicious cervical lymph nodes detected after thyroidectomy

被引:0
作者
Solorzano, Marlin [1 ,2 ,3 ]
Lustig, Nicole [1 ,2 ]
Mosso, Lorena [1 ,2 ]
Espinoza, Martin [1 ]
Santana, Roberto [1 ]
Gonzalez, Hernan [3 ]
Montero, Pablo H. [3 ]
Cruz, Francisco [4 ]
Solar, Antonieta [5 ]
Dominguez, Jose Miguel [1 ,2 ,6 ]
机构
[1] Pontificia Univ Catolica Chile, Fac Med, Dept Endocrinol, Santiago, Chile
[2] Ctr Estudios Traslac Endocrinol Cetren UC, Santiago, Chile
[3] Pontificia Univ Catolica Chile, Fac Med, Dept Oncol Quirurg, Santiago, Chile
[4] Pontificia Univ Catolica Chile, Fac Med, Dept Radiol, Santiago, Chile
[5] Pontificia Univ Catolica Chile, Fac Med, Dept Patol, Santiago, Chile
[6] Diagonal Paraguay 362,4to Piso, Santiago, Region Metropol, Chile
来源
ARCHIVES OF ENDOCRINOLOGY METABOLISM | 2024年 / 68卷
关键词
Papillary thyroid carcinoma; locoregional structural disease; active surveillance; METASTASES; GUIDELINES; MANAGEMENT; RECURRENT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: After initial treatment, up to 30% of patients with papillary thyroid cancer (PTC) have incomplete response, mainly cervical lymph node (LN) disease. Previous studies have suggested that active surveillance (AS) is a possible option for these patients. Our aim was to report the results of AS in patients with PTC and cervical LN disease. Materials and methods: In this retrospective observational study, we included adult patients treated and followed for PTC, who presented with cervical LN disease and were managed with AS. Growth was defined as an increase >= 3mm in either diameter. Results: We included 32 patients: 27 (84.4%) women, age of 39 +/- 14 years, all initially treated with total thyroidectomy, and 22 (69%) with therapeutic neck dissection. Cervical LN disease was diagnosed 1 year (0.3-12.6) after initial management, with a diameter of 9.0 mm (6.0-19.0). After a median AS of 4.3 years (0.6-14.1), 4 (12.5%) patients had LN growth: 2 (50%) of whom were surgically removed, 1 (25%) was effectively treated with radiotherapy, and 1 (25%) had a scheduled surgery. Tg increase was the only predictive factor of LN growth evaluated as both the delta Tg (p < 0.0366) and percentage of Tg change (p < 0.0140). None of the included patients died, had local complications due to LN growth or salvage therapy, or developed distant metastases during follow-up. Conclusions: In selected patients with PTC and suspicious cervical LNs diagnosed after initial treatment, AS is a feasible and safe strategy as it allows effective identification and treatment of the minority of patients who progress.
引用
收藏
页数:7
相关论文
共 21 条
[1]   Treatment of Recurrent or Persistent Cervical Node Metastases in Differentiated Thyroid Cancer: Deceptively Simple Options [J].
Burman, Kenneth D. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (08) :2623-2625
[2]   Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Filetti, S. ;
Durante, C. ;
Hartl, D. ;
Leboulleux, S. ;
Locati, L. D. ;
Newbold, K. ;
Papotti, M. G. ;
Berruti, A. .
ANNALS OF ONCOLOGY, 2019, 30 (12) :1856-1883
[3]   2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J].
Haugen, Bryan R. ;
Alexander, Erik K. ;
Bible, Keith C. ;
Doherty, Gerard M. ;
Mandel, Susan J. ;
Nikiforov, Yuri E. ;
Pacini, Furio ;
Randolph, Gregory W. ;
Sawka, Anna M. ;
Schlumberger, Martin ;
Schuff, Kathryn G. ;
Sherman, Steven I. ;
Sosa, Julie Ann ;
Steward, David L. ;
Tuttle, R. Michael ;
Wartofsky, Leonard .
THYROID, 2016, 26 (01) :1-133
[4]   Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy [J].
Hay, Ian D. ;
Lee, Robert A. ;
Davidge-Pitts, Caroline ;
Reading, Carl C. ;
Charboneau, J. William .
SURGERY, 2013, 154 (06) :1448-1454
[5]   Active Surveillance of Small Metastatic Lymph Nodes as an Alternative to Surgery in Selected Patients with Low-Risk Papillary Thyroid Cancer: A Retrospective Cohort Study [J].
Jerkovich, Fernando ;
Abelleira, Erika ;
Bueno, Fernanda ;
Guerrero, Leidy ;
Pitoia, Fabian .
THYROID, 2022, 32 (10) :1178-1183
[6]   Management of Nodal Disease in Thyroid Cancer [J].
Khokhar, Mamoona ;
Milas, Mira .
SURGICAL CLINICS OF NORTH AMERICA, 2019, 99 (04) :611-+
[7]   Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer [J].
Lamartina, Livia ;
Grani, Giorgio ;
Biffoni, Marco ;
Giacomelli, Laura ;
Costante, Giuseppe ;
Lupo, Stefania ;
Maranghi, Marianna ;
Plasmati, Katia ;
Sponziello, Marialuisa ;
Trulli, Fabiana ;
Verrienti, Antonella ;
Filetti, Sebastiano ;
Durante, Cosimo .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (08) :3036-3044
[8]   Clinical outcomes of a conservative approach in cervical lymph node metastases of thyroid cancer [J].
Maciel, Joana ;
Donato, Sara ;
Simoes, Helder ;
Leite, Valeriano .
CLINICAL ENDOCRINOLOGY, 2021, 94 (03) :460-465
[9]   European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions [J].
Mauri, Giovanni ;
Hegedus, Laszlo ;
Bandula, Steven ;
Cazzato, Roberto Luigi ;
Czarniecka, Agnieszka ;
Dudeck, Oliver ;
Fugazzola, Laura ;
Netea-Maier, Romana ;
Russ, Gilles ;
Wallin, Goran ;
Papini, Enrico .
EUROPEAN THYROID JOURNAL, 2021, 10 (03) :185-197
[10]   Central compartment revision surgery for persistent or recurrent thyroid carcinoma: analysis of survival and complication rate [J].
Molteni, Gabriele ;
Bonali, Marco ;
Mattioli, Francesco ;
Ghirelli, Michael ;
Fermi, Matteo ;
Ferri, Gaetano ;
Andrea, Malagoli ;
Presutti, Livio .
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2019, 276 (02) :551-557